Cube Biotech, an innovator in protein stabilization and purification technologies, announced a leadership transition to continue global growth. Didier Dargent, who has served as Chief Executive Officer, will transition into the role of Executive Chairman. Michael Bencak has been appointed as the new CEO of Cube Biotech and IBA Lifescience, effective immediately. 

Bencak joins Cube Biotech with a track record of leading biotech organizations through growth, transformation, and innovation. With deep industry insight and a passion for advancing science, Bencak is poised to build on Cube Biotech’s legacy of excellence.

Reflecting on the transition, Dargent stated, “It’s been an incredible journey leading Cube Biotech, and I’m proud of what we’ve achieved. As I take on the role of Executive Chairman, I’m confident in Michael’s ability to guide the company into its next phase. With his leadership, we are well-positioned to expand globally and deepen our impact across the biotech sector.”

“I’m incredibly excited to join Cube Biotech and IBA Lifescience,” said Bencak. “These companies are uniquely positioned to shape the future of drug discovery. What inspired me to join is not only the science, but the passion, purpose, and ambition behind it. I truly believe we have the chance to make a meaningful difference.”